Page 5 - Iontech News Today

BioNTech and Pfizer have received a positive opinion from The Committee for Medicinal Products for Human Use (CHMP) for their updated COVID-19 vaccine, as a single dose for individuals 5 years of age and older, regardless of prior vaccination history, in the EU.

With the rise of mRNA-based treatments, the field of oncology is about to go through a significant change.

The European Commission has authorised an updated COVID-19 vaccine from Pfizer and its German partner BioNtech to be used in EU countries' vaccination campaigns this autumn to target the dominant Omicron XBB.1.5 variant, it said on Friday. The Commission authorises its use for adults, children and infants above six months. The European Medicines Authority (EMA) approved the vaccine earlier this week.

The antibody-drug conjugate will be pitted against chemotherapy in a heavily treated breast cancer subpopulation, with hopes of challenging AstraZeneca and Daiichi Sankyo’s blockbuster Enhertu.

Key Insights The considerable ownership by private equity firms in BioNTech indicates that they collectively have a...

Latest round in Covid-19 mRNA vaccine patent litigation battle

At a pivotal moment in cancer vaccine research, the MIT Koch Institute Annual Symposium explored emerging successes and obstacles in the field in areas that include immunology, next-generation tools and models, and mRNA and other vaccine platforms.

Last week, Canada-based Acuitas Therapeutics, Inc. (Acuitas) filed a complaint in the District of New Jersey for declaratory judgment of non-infringement and invalidity against Arbutus Biopharma Corp...

BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Call Transcript August 7, 2023 Operator: Welcome to BioNTech’s Second Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead. Victoria Meissner: Thank you. Good morning and afternoon. Thank you for joining us […]

FRANKFURT (Reuters) -Germany's BioNTech, Pfizer's partner on COVID-19 vaccines, cut its drug development budget for this year after quarterly revenues were hurt by a plunge in pandemic-related demand. Second-quarter revenue dropped to 167.7 million euros ($184 million) from 3.2 billion euros a year earlier, as write-offs on Pfizer's assets ate into profit share payments that BioNTech is entitled to receive from its U.S. partner. "With some uncertainty on the revenue line, w...